Checkpoint Therapeutics (CKPT) Soars 1.24% on Acquisition News

Checkpoint Therapeutics, Inc. (CKPT) shares surged 1.24% today, marking the ninth consecutive day of gains, with a cumulative increase of 3.02% over the past nine days. The stock price reached its highest level since December 2024, with an intraday gain of 1.49%.

On April 24, 2025, Checkpoint Therapeutics, Inc. (CKPT) announced its acquisition by India's Sun Pharmaceutical, which significantly boosted the stock price. This acquisition is expected to bring substantial benefits to CKPT, including enhanced market presence and expanded product offerings. The deal is anticipated to close in the second half of 2025, subject to regulatory approvals and other customary closing conditions.

Despite the positive news from the acquisition, analysts at Lake Street Capital have revised their price target for CKPT from $32.00 to $22.00. This adjustment reflects the analysts' assessment of the company's current valuation and future growth prospects in light of the acquisition. The revised target price suggests a more cautious outlook, considering the potential integration challenges and market dynamics that CKPT may face post-acquisition.